Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.64 |
| ▸ | LPL | P06858 | 7/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298401 | 0.94 | DGAT1 (0.72) | DGAT1LPLLIPGCA1CA2 | |
| SCHEMBL2267580 | 0.86 | DGAT1 (0.56) | DGAT1LPLLIPGAPPCA1 | |
| SCHEMBL21234416 | 0.86 | DGAT1 (0.56) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL17129607 | 0.86 | DGAT1 (0.56) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL10281613 | 0.86 | DGAT1 (0.63) | DGAT1LPLLIPGCA1CA2 | |
| SCHEMBL15981216 | 0.85 | DGAT1 (0.55) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL21568905 | 0.85 | LPL (0.59) | DGAT1LPLLIPGAPPCA1 | |
| SCHEMBL15981217 | 0.85 | DGAT1 (0.55) | DGAT1LPLLIPGF11CA1 | |
| SCHEMBL1656907 | 0.84 | LPL (0.59) | DGAT1LPLLIPGCA1CA2 | |
| SCHEMBL29203355 | 0.84 | DGAT1 (0.55) | DGAT1LPLLIPGF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DGAT1 138/4885LPL 180/4885LIPG 272/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DGAT1 138/4885LPL 180/4885LIPG 272/4885 |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | FAAH, FAAH2, ASAH1 | DGAT1 157/4885LPL 163/4885LIPG 304/4885 |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DGAT1 138/4885LPL 180/4885LIPG 272/4885 |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DGAT1 138/4885LPL 180/4885LIPG 272/4885 |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | DGAT1 138/4885LPL 180/4885LIPG 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.